Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryDec 22, 2017	Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy PRINCETON, N.J., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) in response to the New Drug Application (NDA) resubmission for the...	Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy 16.6 KB
Toggle SummaryApr 7, 2022	Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG) The abstract was accepted by ACOG and will be presented from May 4th – May 6th, 2022 PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that data from the company’s first-year of postmarketing pharmacovigilance...	PDF Version
Toggle SummaryMar 31, 2022	Agile Therapeutics® Partners with Award-Winning Director Maya Albanese on First Twirla® Commercial, Targeting Gen Z Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla (levonorgestrel and ethinyl estradiol) transdermal system, while highlighting the power of female friendships PRINCETON, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc....	PDF Version
Toggle SummarySep 22, 2014	Agile to Present at the 21st Annual BioCentury NewsMakers Conference PRINCETON, N.J., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive...	Agile to Present at the 21st Annual BioCentury NewsMakers Conference 13.8 KB
Toggle SummaryMar 21, 2024	Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024 Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March...	PDF Version
Toggle SummaryMay 6, 2013	Data on Agile Therapeutics Low-Dose Contraceptive Patch (AG200-15) Presented at the First Global Conference on Contraception, Reproduction and Sexual Health Organized by the European Society of Contraception and Reproductive Health (ESCRH)
Toggle SummaryMay 6, 2013	Data on Agile Therapeutics' Low-Dose Contraceptive Patch (AG200-15) Presented at American College of Obstetricians and Gynecologists' (ACOG) Annual Clinical Meeting
Toggle SummaryFeb 14, 2020	FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin Twirla ® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J. , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U.S....	PDF Version
Toggle SummaryJul 24, 2018	FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request Company Plans to Appeal to the FDA’s Office of New Drugs PRINCETON, N.J. , July 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX) (the “Company”), a women’s healthcare company, today announced that the Office Director of the FDA’s Office of Drug Evaluation III (ODEIII) has...	FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request 23.4 KB
Toggle SummaryMay 7, 2012	New Phase III Data Show Agile Therapeutics’ Low-Dose Patch is Comparable to Combination Oral Contraceptive in a Comparator Study